Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Klatskin Tumor Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
Drug
Lead sponsor
PCI Biotech AS
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Gallbladder Cancer, Stage IIIB Hilar Cholangiocarcinoma, Stage IV Ampulla of Vater Cancer, Stage IVA Gallbladder Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVA Pancreatic Cancer, Stage IVB Gallbladder Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Stage IVB Pancreatic Cancer
Interventions
ADH-1, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions
External beam radiation and Cyberknife radiosurgery boost and capecitabine
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Undifferentiated Gallbladder Carcinoma, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions
Erlotinib Hydrochloride, Sorafenib Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
141
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
208
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 12:14 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IVA Extrahepatic Bile Duct Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Extrahepatic Bile Duct Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ricolinostat
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
295
States / cities
Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced May 22, 2026, 12:14 AM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
CT scan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound-Guided Biopsy
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 12:14 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Liver Cancer, Liver Tumor, Hepatocellular Carcinoma, Hilar Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
Florida Hospital Tampa Bay Division
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced May 22, 2026, 12:14 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Cholangiocarcinoma, Hilar Lymphadenopathy, Biliary Stricture
Interventions
PTBD, ERC
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Los Angeles, California • New Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced May 22, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced May 22, 2026, 12:14 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Bile Duct Cancer
Interventions
Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced May 22, 2026, 12:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions
ABC294640, Hydroxychloroquine Sulfate 200 MG
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 22, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 22, 2026, 12:14 AM EDT